| Defining dysbiosis for a cluster of chronic diseases LJ Wilkins, M Monga, AW Miller Scientific reports 9 (1), 12918, 2019 | 283 | 2019 |
| Outcomes of very high‐risk prostate cancer after radical prostatectomy: validation study from 3 centers D Sundi, JJ Tosoian, YA Nyame, R Alam, M Achim, CA Reichard, J Li, ... Cancer 125 (3), 391-397, 2019 | 49 | 2019 |
| Surgical management of high-risk, localized prostate cancer LJ Wilkins, JJ Tosoian, D Sundi, AE Ross, D Grimberg, EA Klein, ... Nature Reviews Urology 17 (12), 679-690, 2020 | 22 | 2020 |
| SKOPE—study of ketorolac vs opioid for pain after endoscopy: a double-blinded randomized control trial in patients undergoing ureteroscopy D Fedrigon, A Faris, N Kachroo, R Jain, M Elia, L Wilkins, J Li, S De, ... The Journal of urology 206 (2), 373-381, 2021 | 19 | 2021 |
| Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8‐10) prostate cancer treated primarily by radical prostatectomy LJ Wilkins, JJ Tosoian, CA Reichard, D Sundi, W Ranasinghe, R Alam, ... Cancer 127 (9), 1425-1431, 2021 | 15 | 2021 |
| Downgrading from biopsy grade group 4 prostate cancer in patients undergoing radical prostatectomy for high or very high risk prostate cancer W Ranasinghe, CA Reichard, YA Nyame, D Sundi, JJ Tosoian, L Wilkins, ... The Journal of Urology 204 (4), 748-753, 2020 | 15 | 2020 |
| Comprehensive management of renal masses in solitary kidneys Y Yasuda, JJH Zhang, W Attawettayanon, N Rathi, L Wilkins, G Roversi, ... European Urology Oncology 6 (1), 84-94, 2023 | 12 | 2023 |
| Does time from diagnosis to treatment of high‐or very‐high‐risk prostate cancer affect outcome? CA Reichard, YA Nyame, D Sundi, J Tosoian, L Wilkins, R Alam, ... BJU international 124 (2), 282-289, 2019 | 12 | 2019 |
| Defining dysbiosis for a cluster of chronic diseases. Sci Rep 9: 12918 LJ Wilkins, M Monga, AW Miller | 10 | 2019 |
| Systemic comorbidity burden using the actions phenotype predicts urologic medication discontinuation following transurethral resection of the prostate JJH Zhang, BA Gill, L Wilkins, RR Ramkumar, DA Shoskes Urology 127, 91-96, 2019 | 7 | 2019 |
| Defining dysbiosis for a cluster of chronic diseases. Sci Rep. 2019; 9 (1): 12918 LJ Wilkins, M Monga, AW Miller Epub 2019/09/11. doi: 10.1038/s41598-019-49452-y. PubMed PMID: 31501492, 0 | 7 | |
| A contemporary analysis of outcomes and modifiable risk factors of ethnic disparities in kidney transplantation LJ Wilkins, YA Nyame, V Gan, S Lin, DJ Greene, SM Flechner, CS Modlin Journal of the National Medical Association 111 (2), 202-209, 2019 | 6 | 2019 |
| Delineating the role of the urinary metabolome in the lithogenesis of calcium-based kidney stones J Agudelo, D Fedrigon, A Faris, L Wilkins, M Monga, AW Miller Urology 167, 49-55, 2022 | 5 | 2022 |
| Defining dysbiosis for a cluster of chronic diseases. Sci Rep 9 (1): 12918 LJ Wilkins, M Monga, AW Miller | 5 | 2019 |
| Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer YA Nyame, L Wilkins, DJ Greene, V Ganesan, C Dai, N Almassi, ... Prostate Cancer and Prostatic Diseases 22 (4), 617-623, 2019 | 2 | 2019 |
| PD07-08 A novel nomogram to predict postoperative biochemical recurrence in patients with localized high-risk prostate cancer R Alam, JJ Tosoian, YA Nyame, L Wilkins, K Yousefi, MR Chappidi, ... The Journal of Urology 197 (4S), e130-e131, 2017 | 2 | 2017 |
| Pd03-09 do patients experience decisional conflict in choosing treatment for kidney stones? L Wilkins, M Monga, K Martinez, D Fedrigon, S Sivalingam The Journal of Urology 206 (Supplement 3), e46-e46, 2021 | 1 | 2021 |
| PD04-07 DEVELOPMENT OF A METABOLOMIC ASSAY TO DETERMINE RISK FOR RECURRENT STONE FORMATION J Agudelo*, D Fedrigon, A Faris, L Wilkins, M Monga, A Miller The Journal of Urology 203 (Supplement 4), e81-e81, 2020 | | 2020 |
| Outcomes of men with ductal prostate cancer undergoing definitive therapy for localized disease. WKB Ranasinghe, DD Shapiro, CA Reichard, MA Elsheshtawi, Y Nyame, ... Journal of Clinical Oncology 38 (6_suppl), 350-350, 2020 | | 2020 |
| BURDEN OF SYSTEMIC COMORBIDITIES USING THE ACTIONS PHENOTYPE PREDICTS DISCONTINUATION OF UROLOGIC MEDICATIONS FOLLOWING TRANSURETHRAL RESECTION OF THE PROSTATE JJ Zhang, B Gill, L Wilkins, R Ramkumar, D Shoskes | | 2018 |
